Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Talk to the deal team
Related deals
St. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn moreItalgas S.p.A. has finalized a rights issue
Italgas S.p.A. has successfully finalized a rights issue, with the capital increase implemented to finance its acquisition of 2i Rete Gas.
Learn moreAskoll Holding has launched a voluntary public tender offer for Askoll EVA
Askoll Holding S.r.l. has successfully finalized a voluntary public tender offer for Askoll EVA S.p.A.
Learn more